Ignite Creation Date:
2024-05-06 @ 2:29 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02057341
Status:
COMPLETED
Last Update Posted:
2020-10-14
First Post:
2014-02-05
Brief Title:
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 pilot study involving a 48-week treatment period designed to test the effectiveness of investigational study drug ARRY-371797 in treating patients with symptomatic genetic dilated cardiomyopathy due to a lamin AC gene mutation and to further evaluate the drugs safety Approximately 12 patients from the US will be enrolled in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C4411004 | OTHER | Pfizer | None |